WESPAC Advisors SoCal LLC Sells 200 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

Share on StockTwits

WESPAC Advisors SoCal LLC lessened its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 26.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 544 shares of the biopharmaceutical company’s stock after selling 200 shares during the quarter. WESPAC Advisors SoCal LLC’s holdings in Bristol-Myers Squibb were worth $28,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Oregon Public Employees Retirement Fund boosted its holdings in shares of Bristol-Myers Squibb by 2,326.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,230,504 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 8,850,072 shares in the last quarter. Winslow Capital Management LLC bought a new position in Bristol-Myers Squibb during the 3rd quarter valued at $378,839,000. Jennison Associates LLC lifted its stake in Bristol-Myers Squibb by 23.4% during the 3rd quarter. Jennison Associates LLC now owns 21,526,559 shares of the biopharmaceutical company’s stock valued at $1,336,369,000 after acquiring an additional 4,080,245 shares in the last quarter. MERIAN GLOBAL INVESTORS UK Ltd lifted its stake in Bristol-Myers Squibb by 6,090.3% during the 4th quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 4,130,436 shares of the biopharmaceutical company’s stock valued at $214,700,000 after acquiring an additional 4,063,712 shares in the last quarter. Finally, BlackRock Inc. lifted its stake in Bristol-Myers Squibb by 2.4% during the 3rd quarter. BlackRock Inc. now owns 114,573,885 shares of the biopharmaceutical company’s stock valued at $7,112,747,000 after acquiring an additional 2,660,326 shares in the last quarter. 73.35% of the stock is owned by institutional investors and hedge funds.

Several brokerages have weighed in on BMY. ValuEngine upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, December 7th. Bank of America decreased their target price on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a research report on Tuesday, February 19th. William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, November 27th. Edward Jones lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. Finally, Credit Suisse Group reaffirmed a “hold” rating and set a $59.00 target price on shares of Bristol-Myers Squibb in a research report on Thursday, December 13th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $59.40.

Shares of BMY stock traded down $0.83 on Friday, hitting $49.06. The company had a trading volume of 5,081,718 shares, compared to its average volume of 20,495,434. The company has a quick ratio of 1.50, a current ratio of 1.61 and a debt-to-equity ratio of 0.40. Bristol-Myers Squibb Co has a twelve month low of $44.30 and a twelve month high of $67.44. The stock has a market cap of $80.88 billion, a PE ratio of 12.33, a price-to-earnings-growth ratio of 2.22 and a beta of 0.81.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.09. The firm had revenue of $5.97 billion during the quarter, compared to analyst estimates of $5.95 billion. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. Bristol-Myers Squibb’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.68 EPS. Sell-side analysts anticipate that Bristol-Myers Squibb Co will post 4.15 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a $0.41 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.34%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.

ILLEGAL ACTIVITY WARNING: “WESPAC Advisors SoCal LLC Sells 200 Shares of Bristol-Myers Squibb Co (NYSE:BMY)” was first reported by Fairfield Current and is the property of of Fairfield Current. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.fairfieldcurrent.com/news/2019/03/15/wespac-advisors-socal-llc-reduces-stake-in-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: What does earnings per share mean?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply